According to the New York Times' live blogging from the F.D.A. hearing on Avandia, the votes are in and it's not looking good for GlaxoSmithKline.
Of the 33 members of the committee, only three voted in favor of keeping Avandia on the market as is. Seven advocated adding more warnings on the drug; ten votes went to restricting its sale or making significant revisions to the label, and twelve committee members voted to take Avandia off the market altogether. The F.D.A. will make a final decision "at a later date."
Is there any indication of how long “a later date” normally takes
The statement says The F.D.A. will make a final decision “at a later date.”